{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-066451","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.601875+00:00","generated_at":"2026-05-18T09:06:35.672919+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CFO Gordon Dunn to depart Quoin Pharmaceuticals; will continue until successor named","bullets":["Mutual separation agreed on July 3, 2025; CFO Gordon Dunn to leave later this year.","Mr. Dunn will continue in his role until his successor is appointed.","Separation agreement anticipated; will be filed as an exhibit to a future Form 8-K or periodic report."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-066451","json":"https://secwatch.observer/filing/0001104659-25-066451.json","markdown":"https://secwatch.observer/filing/0001104659-25-066451.md","text":"https://secwatch.observer/filing/0001104659-25-066451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925066451/0001104659-25-066451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925066451/tm2520110d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:06:35.672919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}